Methods for predicting relative efficacy of a beta blocker therapy based on a B1-adrenergic receptor polymorphism
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 11, 2008
Grant Date -
May 26, 2005
app pub date -
Sep 13, 2004
filing date -
Sep 12, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of .beta..sub.1-adrenergic receptor are provided. The Gly389 .beta..sub.1-adrenergic receptor variants are not as responsive to treatment .beta. blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping .beta..sub.1-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the .beta..sub.1-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully